The urgent need for better treatments for Guillain-Barré Syndrome
Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.
Fierce Pharma5d
Argenx's Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts
Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...
NorthJersey.com2d
The urgent need for better treatments for Guillain-Barré Syndrome
Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long ...
Reading Eagle2d
Gayle June (Weyhenmeyer) Von Bergen OBITUARY
In lieu of flowers, please consider a donation to the GBS/CIDP Foundation International or to Penn State St. Joseph Medical Center. Online condolences can be made at maestumpfuneralhome.com ...
pharmaphorum1d
FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...
Nasdaq6d
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
“We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP, which is on track for an interim responder analysis in 2H’26, along with top-line results from our Phase 2 trial ...
Medscape4d
Paraproteinemic Neuropathy: A Practical Review
Multiple myeloma is part of the spectrum of diseases ranging from MGUS to plasma cell leukemia, and similar to MGUS, is characterized by proliferation of a plasma cell clone and subsequent ...